Studying RNA in Samples From Younger Patients With T-Cell Acute Lymphoblastic Leukemia

This study is ongoing, but not recruiting participants.
Sponsor:
Collaborator:
Information provided by:
National Cancer Institute (NCI)
ClinicalTrials.gov Identifier:
NCT01626183
First received: June 20, 2012
Last updated: June 25, 2012
Last verified: June 2012
  Purpose

RATIONALE: Studying samples of blood and tissue from patients with cancer in the laboratory may help doctors identify and learn more about biomarkers related to cancer

PURPOSE: This laboratory study is looking into RNA in samples from younger patients with T-cell (T) acute lymphoblastic leukemia (ALL).


Condition Intervention
Leukemia
Genetic: RNA analysis
Genetic: proteomic profiling
Other: laboratory biomarker analysis

Study Type: Observational
Official Title: Molecular Taxonomy in Pediatric Cancer- IncRNA Expression in Primary T-ALL

Resource links provided by NLM:


Further study details as provided by National Cancer Institute (NCI):

Primary Outcome Measures:
  • Identification and characterization of IncRNA of pediatric T-cell acute lymphoblastic leukemia [ Designated as safety issue: No ]

Estimated Enrollment: 20
Study Start Date: June 2012
Estimated Primary Completion Date: August 2012 (Final data collection date for primary outcome measure)
Detailed Description:

OBJECTIVES:

  • Characterization of the transcriptomic landscape in diagnosis and relapse of T-cell acute lymphoblastic leukemia (ALL) and the direct comparison with corresponding physiological samples (human thymus).
  • Perform high-throughput transcriptome ribonucleic acid (RNA) sequencing using matched diagnostic T-precursor pediatric ALL samples (peripheral blood or bone marrow).

OUTLINE: Archived peripheral blood and bone marrow samples are analyzed for long non-coding RNA (IncRNA) expression and sequencing.

  Eligibility

Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

DISEASE CHARACTERISTICS:

  • Peripheral blood and bone marrow samples from pediatric patients with diagnosed and relapsed T-ALL

PATIENT CHARACTERISTICS:

  • Not specified

PRIOR CONCURRENT THERAPY:

  • Not specified
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT01626183

Sponsors and Collaborators
Children's Oncology Group
Investigators
Principal Investigator: Iannis Aifantis, PhD New York University School of Medicine
  More Information

Additional Information:
No publications provided

Responsible Party: Peter C. Adamson, Children's Oncology Group - Group Chair Office
ClinicalTrials.gov Identifier: NCT01626183     History of Changes
Other Study ID Numbers: CDR0000735509, COG-AALL12B8
Study First Received: June 20, 2012
Last Updated: June 25, 2012
Health Authority: United States: Federal Government

Keywords provided by National Cancer Institute (NCI):
T-cell childhood acute lymphoblastic leukemia
recurrent childhood acute lymphoblastic leukemia

Additional relevant MeSH terms:
Leukemia
Leukemia, Lymphoid
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
Neoplasms by Histologic Type
Neoplasms
Lymphoproliferative Disorders
Lymphatic Diseases
Immunoproliferative Disorders
Immune System Diseases

ClinicalTrials.gov processed this record on April 15, 2014